Teladoc Health (NYSE:TDOC) Releases FY 2026 Earnings Guidance

Teladoc Health (NYSE:TDOC) updated its FY 2026 earnings guidance on Wednesday. The company provided EPS guidance of -1.050–0.750 for the period, compared to the consensus EPS estimate of -0.930. The company issued revenue guidance of $2.5 billion-$2.6 billion, compared to the consensus revenue estimate of $2.5 billion. Teladoc Health also updated its Q2 2026 guidance to -0.300–0.200 EPS.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on TDOC. Stifel Nicolaus cut their price target on Teladoc Health from $8.00 to $6.00 and set a “hold” rating for the company in a research note on Thursday, February 26th. Wells Fargo & Company cut their price target on Teladoc Health from $8.00 to $6.00 and set an “equal weight” rating for the company in a research note on Thursday, February 26th. Canaccord Genuity Group cut their price target on Teladoc Health from $12.00 to $10.00 and set a “buy” rating for the company in a research note on Thursday, February 26th. Weiss Ratings restated a “sell (e+)” rating on shares of Teladoc Health in a research note on Friday, March 27th. Finally, Oppenheimer cut their price target on Teladoc Health from $12.00 to $7.00 and set an “outperform” rating for the company in a research note on Tuesday, March 3rd. Six investment analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $7.62.

Teladoc Health Stock Performance

Shares of TDOC stock traded down $0.05 during trading hours on Wednesday, reaching $5.95. 5,384,618 shares of the company traded hands, compared to its average volume of 5,914,556. Teladoc Health has a 12-month low of $4.40 and a 12-month high of $9.77. The company has a debt-to-equity ratio of 0.72, a current ratio of 2.77 and a quick ratio of 2.67. The company has a market cap of $1.07 billion, a P/E ratio of -5.22 and a beta of 2.07. The firm has a 50-day moving average price of $5.35 and a 200 day moving average price of $6.47.

Teladoc Health (NYSE:TDOC) last posted its quarterly earnings data on Wednesday, April 29th. The health services provider reported ($0.36) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.02). Teladoc Health had a negative net margin of 7.92% and a negative return on equity of 9.13%. The company had revenue of $613.85 million for the quarter, compared to analysts’ expectations of $613.82 million. Teladoc Health has set its FY 2026 guidance at -1.050–0.750 EPS and its Q2 2026 guidance at -0.300–0.200 EPS. As a group, sell-side analysts predict that Teladoc Health will post -0.89 earnings per share for the current fiscal year.

Insider Buying and Selling at Teladoc Health

In other news, CEO Charles Divita III sold 27,731 shares of Teladoc Health stock in a transaction dated Wednesday, March 11th. The stock was sold at an average price of $5.49, for a total transaction of $152,243.19. Following the transaction, the chief executive officer directly owned 364,784 shares of the company’s stock, valued at $2,002,664.16. The trade was a 7.06% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.70% of the stock is currently owned by insiders.

Teladoc Health News Summary

Here are the key news stories impacting Teladoc Health this week:

• Positive Sentiment: FY?2026 guidance largely in line with or slightly better than Street expectations — company guided FY revenue to $2.5B–$2.6B (matching consensus) and gave an EPS range whose midpoint (~?0.90) is marginally better than the consensus of ?0.93, suggesting full?year performance may be slightly stronger than feared. Press Release
• Positive Sentiment: Revenue for Q1 came in essentially inline with expectations at $613.85M vs. a $613.82M consensus, indicating demand and topline stability in virtual care services. Q1 Results PDF
• Neutral Sentiment: Company commentary and media previews highlighted focus areas such as BetterHelp operations and other metric breakdowns; analysts and outlets are parsing underlying trends beyond headline EPS/revenue. MSN Preview
• Negative Sentiment: Q1 EPS missed estimates: reported (?$0.36) vs. consensus (?$0.34). Teladoc remains unprofitable with negative net margin (~?7.9%) and negative ROE (~?9.1%), which keeps investor focus on when profitability will sustainably improve. Q1 Results PDF
• Negative Sentiment: Q2 guidance was mixed/underwhelming: EPS range of ?0.30 to ?0.20 versus a ?0.22 consensus (midpoint slightly worse) and revenue guidance $597M–$626M where the lower end is meaningfully below the $623.9M consensus — this near?term uncertainty likely drove selling pressure. Press Release

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in TDOC. IFP Advisors Inc lifted its position in shares of Teladoc Health by 412.1% during the 3rd quarter. IFP Advisors Inc now owns 3,989 shares of the health services provider’s stock valued at $31,000 after buying an additional 3,210 shares in the last quarter. PNC Financial Services Group Inc. lifted its position in shares of Teladoc Health by 177.7% during the 4th quarter. PNC Financial Services Group Inc. now owns 4,391 shares of the health services provider’s stock valued at $31,000 after buying an additional 2,810 shares in the last quarter. Van ECK Associates Corp lifted its position in shares of Teladoc Health by 101.4% during the 4th quarter. Van ECK Associates Corp now owns 9,150 shares of the health services provider’s stock valued at $64,000 after buying an additional 4,607 shares in the last quarter. Johnson Financial Group Inc. lifted its position in shares of Teladoc Health by 41,045.8% during the 3rd quarter. Johnson Financial Group Inc. now owns 9,875 shares of the health services provider’s stock valued at $76,000 after buying an additional 9,851 shares in the last quarter. Finally, Cibc World Markets Corp bought a new stake in Teladoc Health during the 4th quarter valued at approximately $82,000. 76.82% of the stock is owned by hedge funds and other institutional investors.

About Teladoc Health

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.